ARDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
ARDELYX, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.09+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $766.53M
- P/E (TTM)
- –
- Dividend yield
- –
ARDELYX, INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales, net | $431.42M | $403.37M | $377.81M | $374.41M | $360.98M | $343.50M | $319.20M | $238.77M | $168.97M | $114.68M | $82.53M | $60.65M | 95.7% | +19.5% |
| IBSRELA | $321.08M | $299.88M | $274.21M | $241.45M | $203.93M | $174.33M | $158.29M | $132.56M | $114.20M | $97.07M | $80.06M | $60.65M | 71.2% | +57.4% |
| XPHOZAH | $110.34M | $103.49M | $103.60M | $132.96M | $157.06M | $169.17M | $160.91M | $106.21M | $54.76M | $17.62M | $2.46M | – | 24.5% | -29.7% |
| Product supply revenue | $11.77M | $15.98M | $15.88M | $10.63M | $15.95M | $9.78M | $11.65M | $8.23M | $5.00M | $8.25M | $6.12M | $5.82M | 2.6% | -26.2% |
| Non-cash royalty revenue related to the sale of future royalties | $7.51M | $8.21M | $8.55M | $8.11M | $4.13M | $3.35M | $2.69M | $1.78M | $967.00K | $368.00K | $0 | – | 1.7% | +81.8% |
| Licensing revenue | $195.00K | $119.00K | $5.09M | $5.09M | $5.08M | $5.08M | $78.00K | $3.08M | $35.07M | $35.81M | $35.81M | $67.80M | 0.0% | -96.2% |
By region
From the segment and revenue-disaggregation notes of Ardelyx's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.